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Objective: Deﬁ  nitive therapy with radical prostatectomy, cryotherapy, or radiation therapy 
generally follows the initial diagnosis of prostate cancer, particularly when men have at least 10 
additional years of life expectancy. There is growing concern regarding the optimal conserva-
tive treatment for patients who decline or do not otherwise qualify for such deﬁ  nitive curative 
treatment. For those patients who choose a watchful waiting approach, it would be beneﬁ  cial 
to know what speciﬁ  c dietary and nutritional methods could potentially slow the progression 
of their disease. In this prospective study, it was our goal to analyze the efﬁ  cacy and safety of 
treating prostate cancer conservatively using the principles of a Mediterranean diet in associa-
tion with a speciﬁ  c prostate nutritional supplement.
Method: Twenty-three men aged 43–74 (median age: 64) with biopsy proven, organ-conﬁ  ned 
prostate cancer who had already declined immediate hormonal therapy and attempts at a cura-
tive cancer treatment agreed to participate in a Chronic Disease Management (CDM) protocol 
highlighted by diet with a speciﬁ  c prostate nutritional supplement. The diet recommended was 
a modiﬁ  ed Mediterranean diet while a patented nutritional prostatitis formula (Peenuts®) was 
the supplement common to all patients. Prostate speciﬁ  c antigen (PSA), a recognized marker 
of prostate disease and prostate cancer activity, was the primary indicator to validate exacerba-
tion or suppression of disease. All men were followed with serial PSA testing, a digital rectal 
exam, an International Prostate Symptom Score index (IPSS-Index) and an expressed prostatic 
secretion (EPS) examination. The primary Gleason sum/score represented in this study was 6 
(n = 11), while Gleason sum patterns 5, 5/6, 6/7, and 7 were also evaluated. Referencing the 
Partin Tables, organ conﬁ  nement was predicted to be 66%. 
Results: Eighty-seven percent of men (n = 20) noted a 58% reduction (range of improvement: 
13%–90%) in PSA over an average of 38.5 months (range: 13–84 months). The remaining 13% 
of men included three men who experienced a mild elevation in PSA of 0.3 ng/ml, 0.7 ng/ml, and 
0.9 ng/ml over 14 months, 42 months, and 34 months, respectively. Fifteen men had completed an 
initial and secondary IPSS-Index while 14 men had undergone an initial and secondary EPS. The 
mean percentage reduction in IPSS-Index was 61% (range: 20%–100% with a median of 55%), 
while men evaluated with EPS examinations noted a mean percentage reduction in white blood 
cells of 77.5% (range: 33%–99% with a median of 82%). These results were evaluated using the 
t-test, Wilcoxon Analysis and the Null Hypothesis and found to be statistically signiﬁ  cant.
Conclusion: Clearly there is a need to develop effective alternative conservative therapies 
for the increasing numbers of prostate cancer patients who will not tolerate deﬁ  nitive curative 
measures or simply choose a conservative approach. Although this prospective study had no 
control arm, was of limited duration and included only 23 participants, it did appear to show 
signiﬁ  cant beneﬁ  t to the majority of prostate cancer patients treated with selective nutritional 
and dietary therapy alone. Such treatments may provide a safe and effective long-term treatment 
alternative for some patients. Further study is encouraged. 
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Prostate cancer is the most commonly diagnosed malignant 
neoplasm among men in North America (Greenlee et al 
2001). Notwithstanding the strides that have been made 
related to diagnosis and treatment, prostate cancer still poses 
a signiﬁ  cant health risk. In 2005, the incidence of prostate 
cancer was noted to be in excess of 232 000 new cases while 
prostate cancer death currently ranks as the second most 
common male cancer death with approximately 32 000 men 
dying from the disease (ACS 2004). According to the SEER 
(Surveillance, Epidemiology & End Result) data and the age 
speciﬁ  c population projections in association with the United 
States Census Bureau, it is estimated that 99 000 men will 
die from prostate cancer in the year 2045 (Chan et al 2004). 
Besides the health risk, there is also concern about the best way 
to pay for expensive prostate cancer treatment in the future 
where an aging population is expected to exhibit high rates of 
prostate cancer detection (Fowler et al 2000). Despite our best 
efforts to cure, failure rates for prostate cancer may be as high 
as 40%–60% in high-risk cases (Teﬁ  lli et al 1999).
Epidemiological studies suggest that diets rich in grains, 
speciﬁ  c vitamins, fruits, and vegetables are associated with 
lower prostate cancer rates than high fat diets associated with red 
meat, dairy product intake, and high dose calcium (Cohen et al 
2000; Michaud et al 2001; Lamb and Zhang 2005; McCann et al 
2005; Walker et al 2005; Wolk 2005). High temperature cooking 
and/or well-done or charred meat contains heterocyclic amines, 
nitrosamines, and polycyclic aromatic hydrocarbons that have 
been shown prospectively to increase prostate cancer risk in the 
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. 
(Cross et al 2005) Dairy products and diets with high calcium 
content have also been found to increase the risk of prostate 
cancer possibly through an increase in phytanic acid levels which 
are also elevated in high meat (protein) diets (Mayer 2005; Xu 
et al 2005). A number of studies have found an association 
between saturated fat and prostate cancer although the precise 
mechanisms are not clear (Giovannucci et al 1993; Dagnelio 
et al 2004; Mydlo 2004). We, therefore, selected a modiﬁ  ed 
Mediterranean diet which includes a high intake of cereals, 
grains, vegetables, fruits, virgin olive oil, beans, garlic, fresh 
herbs, and seafood or poultry (white meat) with an avoidance of 
red meat and dairy products (Trichopoulou et al 2000; Knoops 
et al 2004). 
We know that many prostate cancer patients; up to 73% 
in one study, will take nutritional supplements on their own 
and the typical patient averages about three separate supple-
ments daily (Boon et al 2003; Eng et al 2003; Chan, Elkin, 
et al 2005; Wigul et al 2005). Animal studies, epidemiologi-
cal data, and other evidence suggests that plant-based dietary 
supplements providing indoles, isothiocyanates, phenolics, 
monoterpenes, ﬂ  avonoids, phytosterols, lignan precursors, 
lycopenes, and soy proteins as well as zinc, selenium, Vita-
min E and various other antioxidants may serve as natural 
inhibitors of prostate carcinogenesis and growth (Jain et al 
1999; Chan, Gann, et al 2005; Meyer et al 2005; Schroder 
et al 2005; Shukla and Gupta 2005; Sonn et al 2005). The 
“Peenuts®” product is a standardized, certiﬁ  ed, and patented 
nutritional supplement that contains appropriate levels of 
these ingredients from plant-based sources (Wheeler 2001). 
The formula has been shown to suppress and help resolve 
nonbacterial prostatitis in randomized, placebo-con-
trolled double blinded studies and is readily available 
commercially (Wheeler and Selah 1997; Wheeler 2001). 
Reductions in white blood cell count in the expressed 
prostatic secretions of prostatitis patients were reported 
at 66%–77% using only this nutritional supplement 
(Wheeler and Selah 1997). 
A number of recent studies have suggested that nutritional 
therapies alone could possibly lower the aggressiveness of 
prostate cancer and prevent its progression, but randomized 
clinical trial data so far is very limited and no prospective 
studies have yet identiﬁ  ed an optimal combination of dietary 
measures and nutritional supplementation that can effectively 
control prostate cancer growth.
There are many experts who question whether we are over-
treating prostate cancer. The poignant words of the late Willet 
Whitmore, M.D., may prove most prophetic. To paraphrase, his 
oft-quoted rhetorical question asks, “Is it possible to cure prostate 
cancer when it is necessary?” and, “Is it necessary to cure prostate 
cancer when it is possible?” If we accept that a cure is not always 
possible or even desirable in some cases due to complications, 
surgical risks, side effects, morbidity, cost, and patient choice, this 
leads us to the next logical question, “Is it possible to signiﬁ  cantly 
suppress or slow prostate cancer growth for prolonged periods 
using only nutritional and dietary measures?” The goal of this 
study was to attempt to begin to answer this important question 
by prospectively treating prostate cancer patients exclusively 
with conservative measures including optimal dietary modiﬁ  ca-
tion and standardized complex nutritional supplementation to 
determine the feasibility and effectiveness of such an approach 
as a possible alternative in prostate cancer treatment. 
Methods and materials
Between 1998 and 2004, 23 men (mean age: 63 years) with 
biopsy proven prostate cancer,  who had declined attempts 
at curative cancer treatment and hormonal therapy, were 
given full informed consent and offered the opportunity to Clinical Interventions in Aging 2007:2(1) 155
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try a strictly dietary and nutritionally oriented conserva-
tive protocol. The diet used was a Modiﬁ  ed Mediterranean 
Diet (Prostate Diet) while a patented prostatitis formula 
(Peenuts®) was the nutritional supplement common to all 
patients. By study design, none of the patients had ever been 
exposed to antiandrogen therapy, a luteinizing hormone-
releasing hormone (LHRH) analogue, LHRH antagonist, or 
deﬁ  nitive therapy with surgery, radiation, or cryosurgery. 
All men were followed at varying time intervals with a 
PSA (prostate speciﬁ  c antigen) blood test, while many of 
the men were also followed with the International Prostate 
Symptom Score (IPSS) index and the expressed prostatic 
secretion (EPS) examinations. With the exception of two 
men with Gleason 6/7 components, three men with Gleason 
5/6 components, and one male with a Gleason 7 pattern, 
all men exhibited either a Gleason 5 (n = 6) or a Gleason 6 
(n = 11) pathological pattern. All men were clinically di-
agnosed as T1c (n = 15), T2a (n = 2), T2b (n = 2), or T2c 
(n = 4). Interestingly, all of the men who met the entry criteria 
outlined above except one, enthusiastically chose to treat 
their disease through a dietary and nutritional supplement 
protocol represented by the term Chronic Disease Manage-
ment (CDM) rather than undergo deﬁ  nitive therapy. The 
one male who initially qualiﬁ  ed dropped out after 7 months, 
opting for a radical prostatectomy. CDM therapy is a unique 
cancer concept, but not dissimilar to the conservative holistic 
treatment of diabetes, hypertension, or arthritis whereby pa-
tients learn to live with the disease based on lifestyle changes 
consistent with improved diet, nutritional supplementation, 
stress reduction, and exercise.
While the PSA level is a recognized marker of disease 
activity, it is noted that PSA levels may rise based on any 
combination of prostatitis (nonbacterial inﬂ  ammation in ≥95% 
of cases), BPH (benign prostatic hyperplasia), and/or prostate 
cancer. The IPSS index is a recognized marker associated 
primarily with BPH and prostatitis, while the EPS represents 
the diagnostic biological marker for prostatitis. All men were 
evaluated at varying intervals of surveillance ranging from 13 
months to 84 months (mean: 38.5 months). Three study sub-
jects had a slight increase in their PSA levels of 0.3 ng/ml, 0.7 
ng/ml, and 0.9 ng/ml at 14 months, 42 months, and 34 months, 
respectively. Excluding these three patients with a small rise 
in PSA, the remaining 20 patients (87%) decreased their PSA 
levels by an average of 58% during the study period. 
Statistical analysis
A performance analysis of these 23 patients relevant to 
any change in PSA noted statistical signiﬁ  cance using the 
null hypothesis, t-test, and Wilcoxon analyses. There was a 
signiﬁ  cant decrease in PSA levels (ng/ml) after treatment 
with dietary modiﬁ  cation and the speciﬁ  c herbal supplement 
taken at 2 capsules daily. The p-value (T ≤ t) one-tailed t-test 
is 0.000068. 
The null hypothesis can be postulated from the population 
of 23 patients. The ﬁ  rst observation, u1, is the initial PSA 
value taken. The second observation, u2, is the follow-up PSA 
taken after treatment with the herbal supplement and dietary 
change. H0: u1 – u2 = 0. The null hypothesis postulates that 
the mean value of the difference is zero. There will be no 
signiﬁ  cant difference in PSA levels after herbal supplementa-
tion and dietary change. 
In the alternative hypothesis, the mean is different using 
the observed values; therefore, a two- tailed test is utilized 
(Table 1).
Statistical assessment
There was a signiﬁ  cant decrease in PSA levels (ng/ml) after 
treatment with dietary encouragement and herbal supple-
mentation, 2 capsules daily. Therefore we do not accept 
the null hypothesis that the mean difference is zero. These 
nutritional variables had a signiﬁ  cant effect in reducing PSA 
levels in this subject group. An additional non-parametric test 
was calculated. The results of the Wilcoxon matched-pairs 
signed-ranks test are as follows: W+ = 269.50, W– = 6.50, 
n = 23, p ≤ 6.769005 (Table 2, 3). 
Results
All men within an age range of 43–74 years with a diagnosis 
of prostate cancer (Gleason Score: 5, 5/6, 6, 6/7, 7) who de-
clined standard curative and hormonal therapy were offered 
an opportunity to participate in a conservative quality of life 
Table 1 T-test: Paired two sample for means.   Alpha 
signiﬁ  cance level = 0.05 
   Initial PSA  Follow-up PSA
Mean 6.83  3.36
Variance 8.76  6.34
Observations 23  23
Pearson correlation  0.43 
Hypothesized mean difference  0 
Df 22 
t stat  5.65 
p (T ≤ t) one-tail  0.000006 
t critical one-tail  1.717144 
P (T ≤ t) two-tail  0.000011 
t critical two-tail  2.073875   
Abbreviations: Df, degrees of freedom; PSA, prostate speciﬁ  c antigen.Clinical Interventions in Aging 2007:2(1) 156
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protecting study with the understanding that diet and nutri-
tion could play a signiﬁ  cant role in disease proliferation or 
control. With the exception of the Gleason Score (excluding 
men with a primary Gleason Score of 8, 9, or 10) as a qualify-
ing category of prostate cancer, there was no bias inherent in 
the entrance process. Twenty three men qualiﬁ  ed for study 
evaluation using the PSA levels from the date of diagnosis 
(biopsy date) or the initial clinic appointment date (which-
ever was higher) as the reference PSA value for the starting 
point for data collection. Twenty of 23 men experienced a 
positive response (decrease in PSA levels) relevant to the 
conservative therapy while 3 men noted a mild increase in 
their PSA values. Speciﬁ  cally, 87% of men (n = 20) noted a 
58% reduction (range of improvement: 13%–90%) in PSA 
levels over an average of 38.5 months (range: 13–84 months). 
Using a mean PSA starting point of 6.8 ng/ml, 87% of men 
in the study experienced a mean reduction in PSA of 3.93 
ng/ml (range: 0.9–12.5 ng/ml) over the identiﬁ  ed time frame, 
while the median reduction was 3.45 ng/ml. The three men, 
who experienced a mild elevation in PSA, noted an increase 
of 0.3 ng/ml, 0.7 ng/ml, and 0.9 ng/ml over 14 months, 42 
months, and 34 months, respectively. Overall, the effective-
ness of CDM therapy to suppress prostate cancer was 87% 
using the PSA level as the disease activity marker. 
A urinary assessment with a voiding symptom score 
(IPSS index) and prostatitis evaluation utilizing the EPS 
examination was conducted at the time of baseline (initial 
visit) and follow up evaluations on the majority of the partici-
pants. Fifteen men completed an initial and secondary IPSS 
index while 14 men had undergone an initial and secondary 
EPS. All men reduced their voiding symptom score with an 
average 4.9 points (range: 3–11), while noting an average 
starting score of 9.1 points (range: 2.5–19.5 with a median 
of 8.5). The mean percentage reduction in IPSS index was 
61% (range: 20%–100% with a median of 55%). Relevant to 
the EPS, an average starting point of 283 white blood cells 
(WBCs) per high-powered ﬁ  eld (HPF) (400X) demonstrated 
an average decrease to 65 WBCs/HPF. To state further, a 
mean reduction was noted in the prostatitis marker of 218 
white blood cells (range: 70–495) with a mean percentage 
improvement of 77.5% (range: 33%–99% with a median of 
82%). The reduced number of white blood cells on the EPS 
examinations as well as the improvement in urinary symp-
toms as documented by the average reductions in IPSS index 
scores in this group of men treated with nutritional means 
alone was statistically signiﬁ  cant.
Study analysis and discussion
The possibility of treating prostate cancer conservatively has 
always been intriguing to the patient and a concern for the 
clinician. Previous studies have commonly grouped Gleason 
7 scores with Gleason 5 and 6 scores within the designation 
of moderately well differentiated cancers. Ostensibly, this 
would give patients with Gleason 7 scores improved odds for 
cure while decreasing the chance for success in patients with 
Gleason 5 and 6 scores. This assumes the higher the Gleason 
score, the lower the chance for cure (Teﬁ  lli et al 1999; Nel-
son et al 2002). Increasing evidence through analyses now 
suggests that Gleason 7 prostate cancer responds better than 
a Gleason 8–10 but not as well as a Gleason 5 or 6 (Teﬁ  lli 
et al 1999). Additionally, it is believed that Gleason scores of 
5–7 may comprise almost 90% of all cancers encountered as 
35%–62% of men in most study groups analyzed are identi-
ﬁ  ed in the Gleason 6 category (Teﬁ  lli et al 1999). 
Table 2  T-test: paired two sample for means: 5-alpha reductase 
inhibitors
   Dx. PSA (ng/ml)  Follow up PSA
Mean 6.38461538  2.6153846
Variance 10.2680769  1.1214103
Observations 13    13
Pearson correlation  –0.05984581 
Hypothesized mean difference  0 
Df 12 
t Stat  3.95697795 
p (T ≤ t) one-tail  0.00095184 
t Critical one-tail  1.78228674 
P (T ≤ t) two-tail  0.00190367 
t Critical two-tail  2.17881279   
Note: The p value is statistically signiﬁ  cant at 0.0019.
Abbreviations: Df, degrees of freedom; Dx, diagnosis; PSA, prostate speciﬁ  c 
antigen.
Table 3 T-test: paired two sample for means: non-5-alpha 
reductase inhibitors
   Dx. PSA  Follow-up PSA
Mean 7.06  4.64
Variance 8.987111111  8.707111111
Observations 10  10
Pearson correlation  0.891877977 
Hypothesized mean difference  0 
Df 9 
t Stat  5.529914009 
p (T ≤ t) one-tail  0.000182887 
t critical one-tail  1.833113856 
p (T ≤ t) two-tail  0.000365774 
t critical two-tail  2.262158887   
Note: The p value is statistically signiﬁ  cant at 0.00037. 
Abbreviations: Df, degrees of freedom; Dx, diagnosis; PSA, prostate speciﬁ  c 
antigen.Clinical Interventions in Aging 2007:2(1) 157
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Qualiﬁ  cation for this study included men with the diagno-
sis of prostate cancer who had not been exposed previously to 
antiandrogen therapy, LHRH therapy, or any other deﬁ  nitive 
process of prostate cancer manipulation. Of the 23 patients 
evaluated, 11 men were diagnosed with a Gleason 6 score, 6 
men had a Gleason 5 score, 3 men had a Gleason 5–6 score, 
2 men were noted with a Gleason 6–7 score, while one man 
had a Gleason 7 pattern. The clinical stage assessment noted 
15 men with a T1c, 4 men with a T2c, 2 men with a T2b, 
and 2 men with a T2a stage classiﬁ  cation. Pathologically, the 
biopsy diagnosis ranged from T1a–T2c (Table 4). While the 
number of biopsy cores positive for cancer and the percent-
age of cancer per core varied widely, the percentage of cores 
positive for cancer (identiﬁ  ed at the biopsy procedure) ranged 
from 12.5%–73% (mean: 33%; median 20%) associated with 
a range of biopsy samples from 2–18. This suggests the pres-
ence of signiﬁ  cant disease in the study group. 
In a unique study, Dean Ornish and colleagues at the 
University of California-San Francisco evaluated the abil-
ity of the Vegan Diet (n = 44) to alter the PSA in a com-
parative analysis with a nonrestrictive diet (n = 43) in men 
documented with a Gleason 6 prostate cancer over a one 
year time period (Omish et al 2005). All of the men in this 
study, as in ours, had declined deﬁ  nitive curative treatment 
and hormonal therapy. While the merits of the Vegan Diet 
cannot be disputed as a beneﬁ  t in heart disease prevention, it 
was less clear what effect this diet would have on men with 
known prostate cancer. An average decrease in PSA of 0.25 
ng/ml (4%) identiﬁ  ed in the Vegan group was statistically 
signiﬁ  cant when evaluated in concert with a 0.38 ng/ml (6%) 
rise in the placebo group. While statistically signiﬁ  cant, the 
difference was nonetheless modest at one year. This study 
result does not suggest a lack of beneﬁ  t to the Vegan Diet, but 
rather demonstrates that the impact of diet alone on prostate 
cancer may be modest. 
In our prospective study, we evaluated the beneﬁ  t of a 
modiﬁ  ed Mediterranean diet on known prostate cancer pa-
tients with Gleason scores of 5–7. The Mediterranean diet is 
recognized worldwide for its health beneﬁ  ts systemically but 
more speciﬁ  cally its promotion of cardiovascular health and 
cancer avoidance (colorectal, breast, pancreas, prostate, and 
endometrial) properties (Trichopoulou et al 2000; Knoops 
et al 2004; Giugliano and Esposito 2005; Williams and Hord 
2005). By design, men were asked to avoid red meat and dairy 
products including eggs in an effort to decrease saturated 
fat. It is commonly recognized that animal fat and dairy fat 
may play a role in prostate cancer proliferation (Giovannucci 
et al 1993; Cohen et al 2000; Michaud et al 2001; Margolis 
and Carter 2002; Dagnello et al 2004; Mydlo 2004; Cross 
et al 2005; Lamb and Zhang 2005; Mayer et al 2005; McCann 
et al 2005; Walker et al 2005; Wolk 2005; Xu et al 2005). 
Unlike the Ornish cohort, men did not use soy in their diets. 
Table 4 Chronic disease management protocol noting PSA response to 5–alpha reductase inhibitors (5-ARIs) versus non-5-ARIs 
(August 2005)
5-ARIs Non-5-ARIs
Dx. PSA   Gleason  Follow up  Surveillance  Percent  Dx. PSA  Gleason  Follow up  Surveillance  Percent
(ng/ml)  Score   PSA  Months  change  (ng/ml)   Score   PSA  Months  change
8.5  5  3.1  72 64%  7.0  5  2.4  62 66%
5.4  6  2.1  41 61%  11.7  5/6  5.8  60 50%
2.1  5  2.8  42 +33%  4.7  6  1.7  72 64%
7.3  5/6  4.5  40 38%  6.9  6  5.1  19 26%
3.2  6  2.0    21 38%  6.9  6  6.0  38 13%
4.4  6/7  1.7  39 61%  9.1  6  5.5  58 40%
6.8  5  1.7  49 75%  3.0  5  0.8  24 73%
8.4  6  1.8  18 79%  6.2  5  4.1  84 34%
4.4  6/7 4.7 14  +7%  11.4  6  12.3 34  +8%
14.4  6  1.5  29 90%  6.6  6  1.8  24 73%
4.1 6  1.6  15  61 
6.1 5/6  1.3  13  79 
8.6 7  2.9  17  66% 
Average   5.9  2.44  32 Months  52%  Average  5.65  4.55  48 Months  43.1%
starting         starting
PSA       PSA
6.44  ng/ml       7.35  ng/ml
Notes:  Average reduction in PSA with 5-ARIs = 4.0 ng/ml; average reduction in PSA with non-5-ARIs = 2.8 ng/ml.
Abbreviations:  ARIs, alpha-reductase inhibitors; Dx, diagnosis; PSA, prostate speciﬁ  c antigen.Clinical Interventions in Aging 2007:2(1) 158
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Fresh fruits and cruciferous vegetables belonging to the bras-
sica classiﬁ  cation were highlighted while the oil of choice 
was virgin olive oil.
Beyond the modiﬁ  ed Mediterranean Diet, our study group 
used a complex nutritional supplement called Peenuts® that 
was originally developed to treat prostatitis. This formula 
represents a unique, synergistic blend of vitamins, miner-
als, amino acids, and herbs. These ingredients have been 
shown individually to affect cellular oxidation, inﬂ  amma-
tion, and immune function, while less clearly offering ad-
ditional potential beneﬁ  ts from beta-sitosterols (PDR 2000; 
MSKEB 2004). While using this formula, previous clinical 
investigations have shown an improvement in the EPS and 
voiding symptoms (Wheeler and Selah 1997). The EPS is the 
recognized diagnostic marker for prostatitis as shown through 
the historic work of Stamey, Meares, and others (Blacklock 
and Beavis 1974; Anderson and Fair 1976; Drach et al 1978; 
Anderson and Weller 1979; Schaeffer et al 1981), while 
voiding symptoms are common to the diagnosis of benign 
prostatic hyperplasia and prostatitis. 
The concept of looking at prostatitis within this study 
group was prompted by previous research from the Ameri-
can Association of Cancer Research (AACR) that supports a 
role for prostatitis in the evolution of prostate cancer (AACR 
2001; Nelson et al 2004; Smith and Missailidis 2004). It is 
postulated that the cellular oxidative stress associated with a 
chronic inﬂ  ammatory process leads to proliferative inﬂ  amma-
tory atrophy with subsequent evolution of free radicals through 
oxidative change eventually resulting in DNA alteration (cel-
lular mutation), prostatic intra-epithelial neoplasia (PIN), and 
cancer (AACR 2001; Nelson et al 2004). While it is beyond the 
scope of this article to review these ﬁ  ndings in greater depth, it 
is well known that the process of inﬂ  ammation is commonly 
associated with organ speciﬁ  c cancers including but not limited 
to cancer of the esophagus, colon, stomach, liver, lung, and 
cervix (Balkwill and Mantovani 2001; Coussens and Werb 
2002; Smith and Missailidis 2004).
Within our study group, the mean PSA at the time of 
diagnosis was 6.8 ng/ml (range: 2.1–14.4 ng/ml). A statisti-
cally signiﬁ  cant reduction in mean PSA of 3.4 ng/ml was 
validated using the t-test, Wilcoxon analysis and the null 
hypothesis (Table 5). The mean percentage reduction in 
PSA was 50% while the likelihood for organ conﬁ  nement in 
this group was 66% referencing the Partin Prediction tables 
(Partin et al 1997, 2001).
While the topic of prostatitis and its role in prostate 
cancer evolution is likely to remain controversial for the 
immediate future, the topic’s relevance may be best left for 
the healthcare provider and the patient to decide. Based on an 
average percent reduction in the WBCs (a universal marker 
for inﬂ  ammation) of 77.5% associated with the EPS, there 
appears to be sufﬁ  cient clinical indication to support the ad-
dition of a scientiﬁ  cally validated prostatitis therapy to any 
long-term prostate cancer management protocol. The relative 
failure of the Vegan diet in the Ornish study to signiﬁ  cantly 
suppress prostate cancer (based on PSA analysis) supports 
this hypothesis.
Additionally, it is not unreasonable to suggest the noted 
reduction in PSA in our study is based mainly on the im-
provement in prostatitis as it is well known that prostatitis 
is a common cause of PSA elevations. However, the long 
average duration of the reduction in PSA levels at over 
3 years in patients with known prostate cancer receiving no 
other therapy would suggest that the treatment is acting di-
rectly on the prostate cancer. Only further study will be able 
to determine if this conclusion is accurate. At the very least, 
we can say that the nutritional component complements the 
diet and may well enhance the durability of response seen 
in the study patients.
There is a clear indication that the nutritional treatment 
evaluated had an impact on voiding symptoms, as there was 
a mean percentage reduction in the IPSS index of 61%. This 
is consistent with ﬁ  ndings from a previously performed ran-
domized, double blind, placebo controlled study (Wheeler 
and Selah 1997). This response exceeds that of any prostate or 
prostatitis nutritional formula such as saw palmetto described 
in the world medical literature suggesting a synergistic ef-
fect from the particular blend of nutrients selected (Kaplan 
et al 2004).
One gentleman aged 54, who had initially qualiﬁ  ed for the 
study, decided on a radical prostatectomy despite performing 
quite well at 7 months. Importantly, the delay in surgery had 
no adverse effect on the outcome, as his PSA was 0.0 ng/ml, 
1 year post-prostatectomy. While further research could eval-
uate the potential beneﬁ  t of this protocol to any ultimate out-
come, the delay in deﬁ  nitive treatment allowed for improved 
awareness and decision making on the part of the patient and 
his family. Alternatively, research may demonstrate the use 
of the Peenuts® formula or similarly validated supplements 
to be a reasonable ﬁ  rst step in avoiding additional biopsies 
in patients where prostatitis is present. 
While the use of the modiﬁ  ed Mediterranean diet and a 
prostate nutritional supplement has been shown to be effec-
tive, additional ingredients and/or products may be added to 
enhance the collective beneﬁ  t in the prostate cancer disease 
suppression process. Beyond the modiﬁ  ed Mediterranean Clinical Interventions in Aging 2007:2(1) 159
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Wheeler 
diet and the Peenuts® nutritional formula that were used by 
all patients, 17 patients used an active form of vitamin D, 13 
patients used an anticholesterolemic agent, 14 patients used 
omega-3 fatty acids, 13 patients used a 5-alpha reductase 
inhibitor (5-ARIs), 7 patients used a COX II inhibitor, and 
4 men used an alpha-blocker. When the men using 5-ARIs 
were studied versus the men who didn’t use them, there 
was a 52% reduction in PSA in the 5-ARIs group (n = 13) 
over 32 months versus a 43% reduction in the cohort not on 
5-ARIs (n = 10) over 48 months. This suggests a relatively 
insigniﬁ  cant beneﬁ  t in PSA reduction relevant to the men 
on the 5-ARIs at this point in the study. Interestingly, when 
the nutritional supplement formula was evaluated alone 
(n = 4), a reduction in mean PSA of 53.8% over 41.3 months 
of surveillance was noted. While this ﬁ  nding is potentially 
quite signiﬁ  cant, it would be premature to draw any conclu-
sions from such a small sampling size and a larger study with 
additional patients would need to be completed before the 
issue can be properly addressed.
Conclusions
Prostate cancer is recognized as the number one male cancer 
health risk with a new case diagnosed every 3 minutes. With 
baby boomers aging and healthcare costs rising (Gelman 
2004), an opportunity to examine novel concepts for the 
care of patients diagnosed with prostate cancer could not 
be more relevant. When a radical prostatectomy is success-
fully performed for a cure, consideration should be given to 
the potential average beneﬁ  t of adding 3 years, 1.5 years, 
and 0.4 years to the life of a typical man in his 50s, 60s, or 
70s, respectively. When this beneﬁ  t is weighed against the 
possibility of failure to cure and the associated morbidity, 
pain, surgical risks, complications, side effects, and costs, 
an effective dietary and nutritional protocol may present a 
reasonable alternative (Coley et al 1997).
When all of these factors are considered in our aging 
population together with the risks of a signiﬁ  cant decrease 
in the quality of life even in successful cases of deﬁ  nitive, 
curative therapy, a conservative approach may be welcomed 
as a viable ﬁ  rst choice in Gleason 5 and 6 prostate cancer 
patients by Governmental agencies such as Medicare, the 
healthcare insurance industry, and patients alike. Critical 
to research regarding the concept of living with the disease 
is to locate and allocate funding to study this protocol and 
similar programs in greater depth with additional patients 
followed over a longer period of time. This study has perhaps 
provided the ﬁ  rst step in our improved understanding of the 
concept of nutritional therapy of prostate cancer. Beyond 
the issue of prostate cancer treatment is the potential role of 
prevention. Ultimately through this research effort and that 
of others, the landscape of prostate cancer treatment will 
become better deﬁ  ned. 
Addendum
Description of the patented prostatitis 
formula 
Peenuts® is a standardized formula for prostate health readily 
available around the world. The formula is a proprietary blend 
of vitamins, minerals, amino acids, and beta sitosterols. The 
following ingredients make up this formula:  
•  Vitamins–C, B6, E
•  Minerals–zinc, selenium, 
•  Herbs–Saw palmetto, Pygeum africanum, stinging nettle, 
pumpkin seed, Echinacea purpurea, garlic, ginkgo bi-
loba
•  Amino acids–L-glycine, L-alanine, L-glutamic acid.  
Modiﬁ  ed Mediterranean Diet
The Modiﬁ  ed Mediterranean Diet encompasses all of the 
traditional components of a standard Mediterranean Diet 
including fresh fruits and vegetables, olive oil, Omega 3 
fatty acids, ﬁ  sh, tomato and tomato-related products, and red 
wine. The modiﬁ  cation to this diet comes with a limitation 
of pasta as well as an avoidance of red meat and dairy fat 
associated with a fatty acid called Arachidonic acid found 
in the saturated fats of these food items. Based on references 
sited in the bibliography, Arachidonic acid has been shown 
to cause prostate cancer to grow aggressively in vitro.
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